Board summary
Key figures
91,717
Registered population
54.5% aged 18–64
28.1%
Aged 65+
ICB 21.9% · England 17.9%
5.0%
Ethnic minority (non-White)
2.0% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
15,948
Hypertension register
+5.47% in 3 yrs · England +5.60%
1,018
SMI register
83.6% of Chichester's
1,799
COPD register
Reviews -4.82% in 3 yrs
Forecast to 2030
18,177
Hypertension patients, 2030
+2,229 on today
70.9%
QRISK ≥20% on statins, 2030
+4.58pp over 3 yrs
5.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension control and recording exceed England.
Hypertension treatment to target is 72.8% (Chichester 72.8%, ICB 69.1%, England 70.3%), with 92.6% having a recent blood pressure reading (England 90.0%).
Eleven three-year trends lag behind England.
Across 25.0 measures, 11 trail England's three-year change, including heart failure reviews (-2.8%), COPD reviews (-4.8%), and smoking cessation support (-4.8 pp).
Preschool second-dose MMR trails first dose.
Age-five MMR coverage is 94.5% for dose 1 versus 88.1% for dose 2 (95.0% target), with a 16 pp difference at Parklands Surgery.
Population, age and ethnicity
Older patients represent 28.1% of the list, well above England's 17.9%
The PCN registers 91,717 patients across eight practices. Older people form 28.1% of the list (25,781 patients), exceeding Chichester (26.9%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Working-age adults (18–64) comprise 54.5% (Chichester 55.8%, ICB 60.5%, England 62.7%) and children (0–17) 17.4% (Chichester 17.3%, ICB 17.7%, England 19.6%). Census estimates show 95.0% White residents and 5.0% ethnic minority groups (Asian 2.0%), compared with Chichester (95.4%), the ICB (91.0%), and England (81.1%). Ethnicity reflects local resident Census estimates rather than registered GP records, and projected 2.1% growth to 2030 uses an unverified methodology.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Chichester local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Chichester LA) | 2,453 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Chichester LA) | 1,285 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Chichester LA) | 8.7 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
With 0.0% Core20 residence, clinical vulnerability in the PCN may be largely non-spatial
The PCN records an average IMD decile of 6.1 (Chichester 6.2, NHS Sussex ICB 6.1, England 5.5), with 0.0% of registered patients living in Core20 areas (England 21.0%, NHS Sussex ICB 9.2%). Across member practices, Core20 share is 0.0%, while practice average IMD deciles range from 5.1 at Selsey Medical Practice to 7.4 at Southbourne Surgery. As area deprivation deciles may not capture pocket vulnerability, inequality efforts could prioritise non-spatial clinical cohorts, including 1,018 severe mental illness and 536 learning disability patients.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,018
SMI register
1.10% recorded prevalence
536
Learning disability register
0.58% recorded prevalence
46
Care homes, 1,656 beds
In the PCN catchment
8.5%
Provide unpaid care
Chichester, Census 2021
The PCN records 1,018 severe mental illness patients (1.1%) and 536 on the learning disability register (0.6%), comprising 83.6% and 81.8% of Chichester's totals. The catchment contains 46 care homes with 1,656 beds. Chichester district recorded an 8.5% unpaid care rate and 9 rough sleepers in 2025.
Severe mental illness: physical health checks
SMI blood pressure recording reached 83.0% (England 83.4%) and BMI checks 83.1% (England 82.1%), but smoking cessation support fell 4.8 pp over three years (England +0.1 pp) to 87.1% (England 94.2%). Missing elements cannot imply completed checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
15,948
Hypertension register
+5.47%
Register growth, 3 yrs
Chichester +5.87% · England +5.60%
+3.18pp
BP control, under 80
≤140/90 · +1.90pp aged 80+
+2,229
More patients by 2030
Forecast 18,177 (19.14%)
Hypertension case-finding and control
The PCN records 15,948 patients on its hypertension register, a crude prevalence of 17.2%, compared with 17.4% in Chichester, 16.3% in NHS Sussex ICB, and 15.2% in England. Practice prevalence ranges from 11.6% at Parklands Surgery and 14.3% at Lavant Road Surgery to 23.4% at Selsey Medical Practice. Over three years, prevalence rose +5.5% (+0.9 pp), matching NHS Sussex ICB (+5.5%) and near England (+5.6%). Process measures show 92.6% of patients have a recent blood pressure reading (England 90.0%) and 72.8% are treated to target (England 70.3%). Crude prevalence is unadjusted for age. Treatment to target above England is consistent with strong clinical control; recorded practice differences do not establish under-detection and remain untested locally.
Lipids and statins
Among patients with QRISK ≥ 20%, 60.6% receive lipid-lowering therapy, compared with 60.4% in Chichester, 60.0% in NHS Sussex ICB, and 63.6% in England, despite +8.2% three-year growth. Coverage trailing England could reflect recall or initiation gaps, which would require practice audit to confirm.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 216,466 | £2.10 | £2.42 | £1.86 | £454,579 |
| Cardiovascular (all), 2025 | 269,323 | £2.98 | £3.32 | £3.33 | £802,583 |
In 2026, the PCN prescribed 216,466 lipid-modifying items at £2.10 each (Chichester £2.11, NHS Sussex ICB £2.42, England £1.86), spending £51,952 more than at England's unit cost. Unit cost does not reflect treatment appropriateness. Higher unit costs than England could reflect formulary choices, though unit cost does not establish prescribing efficiency or treatment appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+5.69%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.07%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.9% (1,799 patients), matching England (1.9%), but 12-month reviews fell 4.8% over three years to 75.5% (England +2.8%). Asthma prevalence is 7.5% (6,644 patients; England 6.6%), with reviews rising +5.7% (England +4.4%) to 68.5% (England 65.7%). Applying this rate across the register leaves an estimated scale gap of about 2,100 (2,094) unreviewed asthma patients. Prescribing reached 1,751 items per 1,000 aged 5-19 (England 1,488). Divergent review trends could reflect differing recall prioritisation, untested locally.
Cancer register and children's immunisation
Cancer prevalence is 5.1% (4,694 patients), above England (3.8%). In childhood immunisations, 6-in-1 complete course at 24 months reached 95.3% (NHS Sussex ICB 92.9%). However, age-five MMR dose 2 coverage is 88.1% (sitting 6.9 pp below the 95.0% target), creating a 6.4 pp difference from dose 1 (94.5%). The 4-in-1 booster reached 87.2% (sitting 7.8 pp below the 95.0% target). Dose attrition could reflect recall timing gaps, untested locally.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
Across NHS Sussex ICB in 2022, 58.5% of cancers with a known stage (4,799 of 8,209) were diagnosed at stage 1 or 2, exceeding England (55.3%) but sitting 16.5 pp below the 75.0% national ambition by 2028. Closing this gap requires about 1,360 additional early-stage diagnoses annually across the ICB. Staging completeness was 64.3% (8,209 of 12,766 registered cancers; England 67.0%). Within the PCN, cervical screening coverage for women aged 25 to 49 is 71.1% (England 66.8%), but falls to 57.0% at Cathedral Medical Group. Lower cervical screening uptake at specific practices may indicate non-responder follow-up gaps that could be tested through practice audit.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At University Hospitals Sussex NHS Foundation Trust, distance to the 85.0% 62-day referral to treatment standard is -19.8 pp, distance to the 96.0% 31-day combined treatment standard is -19.2 pp, and distance to the 75.0% 28-day faster diagnosis standard is -1.0 pp. For NHS Surrey and Sussex Integrated Care Board, distance to the 62-day standard is -13.5 pp, distance to the 31-day standard is -5.6 pp, and distance to the 28-day standard is 4.3 pp. These measures capture hospital and system pathway pressures rather than PCN referral volume.
| Pathways within standard (%) | Sussex | Portsmouth | Southampton | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 66.81 | 75.07 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 94.78 | 86.76 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 75.20 | 74.44 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | Portsmouth | Southampton | England |
|---|---|---|---|---|
| MRI | 5.62 | 50.36 | 14.30 | 21.40 |
| CT | 8.57 | 13.06 | 16.47 | 9.92 |
| Echocardiography | 0.39 | 32.75 | 14.58 | 28.48 |
| Colonoscopy | 39.35 | 82.52 | 15.84 | 30.83 |
| Gastroscopy | 20.02 | 74.88 | 18.47 | 29.02 |
| All 15 DM01 tests | 12.95 | 51.96 | 20.84 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In the provisional June 2026 Community Services Dataset, 72.7% of all contacts with Chichester local authority residents were for adults aged 65 and older (56,740 of 78,050 contacts). This concentration reflects community health delivery across the wider local authority population rather than PCN-specific activity, indicating high local dependence on community and intermediate care.
Practice variation and patient experience
High QOF domain achievement does not establish complete population reach across member practices
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Langley House | 101 | 0.0 | 70.9% | 80.3% | 87.5% |
| Tangmere | 99 | 0.0 | 81.1% | 81.0% | 82.9% |
| Parklands Surgery | 107 | 0.0 | 57.1% | 70.4% | 78.4% |
| Witterings | 130 | 0.0 | 44.3% | 64.8% | 77.1% |
| Selsey Medical | 153 | 0.0 | 40.9% | 61.7% | 74.8% |
| Cathedral Medical | 113 | 0.0 | 41.2% | 79.9% | 74.1% |
| Lavant Road | 100 | 0.0 | 43.5% | 75.8% | 69.4% |
| Southbourne | 114 | 0.0 | 21.6% | 77.7% | 67.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven of 25 measures trail England over three years, led by heart failure reviews
Across 25 compared measures, 11 trail England's three-year change. The widest lags are heart failure reviews (-2.8% vs +8.7% in England, an 11.55 points gap), breast screening (+0.5% vs +8.4%), COPD reviews (-4.8% vs +2.8%), and smoking cessation support (-4.8 pp vs +0.1 pp). Conversely, relative strengths outpacing England include mental health BMI checks (+7.2 pp vs +5.1 pp), QRISK ≥ 20% lipid therapy (+8.2% vs +6.2%), and mental health blood pressure checks (+6.1 pp vs +4.4 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Breast screening (53-70)
COPD reviews
Diabetes HbA1c control
Smoking support (SMI)
BMI record (SMI)
QRISK statin treatment
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Chichester | Asset | PCN | Chichester |
|---|---|---|---|---|---|
| Care homes (catchment) | 46 (1,656 beds) | n/a | Schools (catchment) | 74 | n/a |
| Children's centres | 5 | 6 | Places of worship | 91 | 153 |
| Libraries | 4 | 5 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 1 | 1 | Carers support groups (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 16 | 31 | Primary academies | 20 | 22 |
| Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Preschool second-dose MMR recall
Age-five MMR coverage drops 6.4 pp from dose 1 (94.5%) to dose 2 (88.1%, cohort 218), sitting 6.9 pp below the 95.0% target. For discussion: practices could audit age-five cohorts missing a second MMR dose and align recall prompts with pre-school booster invitations. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Chronic review and smoking recall
Three-year changes trail England across 11 of 25 measures, including smoking support (-4.8 pp vs +0.1 pp, at 87.1% vs 94.2%), heart failure (-2.8% vs +8.7%), and COPD reviews (-4.8% vs +2.8%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Structured annual asthma review recall
With 68.5% of the 6,644 asthma register recorded as reviewed in 12 months (England 65.7%, Chichester 67.5%, ICB 62.5%), an estimated scale gap of 2,094 (about 2,100) patients remains. For discussion: practices could pair inhaler prescribing checks with standardised annual review invitations and flexible clinic slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Frailty and multi-morbidity service planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Non-spatial inclusion health outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation recall audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case-finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool immunisation recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Option 1 · Preschool second-dose MMR recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Chronic review and smoking recall (p12) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) · Patients with COPD who had a review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
